Background. Clinical trials have demonstrated the effectiveness of human immunodeficiency virus (HIV) pre-exposure prophylaxis (PrEP) for reducing HIV acquisition. Understanding how HIV care providers are prescribing PrEP is necessary to ensure success of this prevention strategy.
More that 40 000 persons are diagnosed with human immunodeficiency virus (HIV) infection in the United States annually [1] , and reducing new infections is a public health priority. Clinical trials have demonstrated that the use of daily antiretroviral pre-exposure prophylaxis (PrEP) is safe [2] and substantially reduces HIV acquisition by men who have sex with men (MSM) [3] , heterosexual men, and women recruited as individuals [4] or in HIV-discordant couples (ie, one partner has HIV infection, and the other does not) [5] and persons who inject drugs (PWID) [6] . In 2014, the Centers for Disease Control and Prevention (CDC) published formal clinical practice guidelines: Preexposure Prophylaxis for the Prevention of HIV Infection in the United States [7] . Surveys of primary care providers (PCPs) and HIV specialists have examined their attitudes and experience offering PrEP to patients at risk for HIV infection [8] [9] [10] [11] [12] , but nationally representative data describing the prescription of PrEP by HIV care providers are lacking. Human immunodeficiency virus care providers, because of their familiarity managing HIV infection including the prescription of antiretroviral medications, may be early adopters of PrEP for their HIV-negative patients who remain at risk of HIV infection. Knowledge of their prescribing practices could inform the development of strategies to enable more providers to prescribe PrEP. To address this knowledge gap, we surveyed a national probability sample of US HIV care providers who also provided care to HIV-negative patients to determine (1) the percentage and characteristics of providers who had prescribed PrEP and (2) the percentages of patients in different subgroups for whom they had prescribed.
METHODS

Sample Design and Data Collection
The Medical Monitoring Project (MMP) is an ongoing HIV surveillance system that, from 2009 to 2014, used a 3-stage probability sampling design to assess the clinical and behavioral characteristics of HIV-infected adults receiving outpatient medical care for HIV in the United States [13, 14] . Data describing provider characteristics and practices were obtained from the 2013-2014 MMP Provider Survey, using a national probability sample of HIV care providers derived from the MMP facility sample. In brief, 16 states and 1 territory were selected using M A J O R A R T I C L E probability proportionate to size sampling at the first stage, with size based on estimates of the number of acquired immune deficiency syndrome (AIDS) cases in 2002. All sampled areas agreed to participate. At the second stage, 622 facilities providing HIV care within these areas were sampled using probability proportionate to size sampling based on the number of persons receiving care for HIV infection; of these, 505 agreed to participate (81% participation rate). A list of all physicians, physician assistants, and nurse practitioners who had completed their training and provided HIV care (defined as ordering CD4 counts or HIV viral load tests, or prescribing antiretroviral medications) between January 1 and April 30, 2012 was obtained from each facility sampled for MMP, resulting in a total of 2208 HIV care providers. All of these providers were invited to participate in the survey between June 2013 and January 2014. In all, 2023 (91.7%) were determined to be eligible, and surveys were returned by 1234 eligible providers (American Association of Public Opinion Research, Response Rate 3 adjusted provider response rate [15] 64.0%) from 391 HIV care facilities. Data collection methods have been described elsewhere [16] .
Analytic Methods
Among 1234 respondents, 935 provided care to HIV-negative patients and provided information about whether they had ever prescribed PrEP. Among these providers, we estimated the percentage of providers who reported ever having prescribed continuous daily dosing of tenofovir/emtricitabine for HIV PrEP.
We estimated percentages and corresponding 95% confidence intervals (CIs) for provider demographics, qualifications and experience, and practice characteristics. Demographics included age, gender, and race/ethnicity (white, non-Hispanic/Latino; black/African American, non-Hispanic/Latino; Hispanic/ Latino; or other) and sexual orientation (heterosexual; or lesbian, gay, or bisexual). Qualifications and experience included profession (physician, ie, Doctor of Medicine [MD] or Doctor of Osteopathic Medicine [DO]), nurse practitioner, or physician assistant), physician board certification, which included infectious diseases (ID), internal medicine, family medicine, pediatrics, or other/not board certified (physicians who were board certified in ID were classified as ID physicians regardless of any additional board certifications), years caring for HIV patients, HIV patient caseload, and the percentage of patients for whom the provider currently, for any reason, deferred prescribing antiretroviral therapy (ART). Respondents reported the percentage of non-white patients and MSM in their practices, which were then categorized to ≤50% vs >50%. Whether providers' practices received Ryan White HIV/AIDS Program (RWHAP) funding or provided onsite adherence counseling was ascertained using data from a previous MMP facility survey [17] . Among providers who had ever prescribed PrEP, we estimated the percentages who reported having prescribed for MSM, men who have sex with women (MSW), women who have sex with men (WSM), uninfected partners in HIV-discordant couples attempting to conceive, PWID, or others. We computed weighted prevalence estimates with 95% CIs of demographic, professional, and practice characteristics of providers who reported having prescribed PrEP, and we used Rao-Scott χ 2 tests and univariate logistic regression to assess associations between those characteristics and PrEP prescription. We used multivariate logistic regression to assess independent predictors of PrEP prescription, including in the model variables that were conceptually and statistically (P < .05%) associated with PrEP prescription. We considered estimates with a coefficient of variation greater than 0.3 unreliable. The data were weighted based on probability of selection, and adjustments were made to the probability weights based on factors associated with nonresponse such as number of HIV care providers practicing at the facility and provider profession. The sample design and weighting methods allow inference to all HIV care providers at outpatient HIV healthcare facilities in the United States between January 1 and April 30, 2012. We used SAS/STAT (version 9.3) and SUDAAN (version 11) procedures for the analysis of complex sample survey data.
Ethics Statement
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RESULTS
Among US HIV care providers in 2013-2014, an estimated 87% (95% CI, 83-92) also provided care for patients without HIV infection. Among these providers, 41% were female and 14% were lesbian/gay/bisexual. Although 38% provided HIV care for ≤50 patients, 39% cared for 51-200 patients, and 23% cared for >200 patients; 48% reported having >50% MSM in their practices (Table 1) . In all, 26% (95% CI, 20-31) of HIV care providers who also provided care for patients without HIV infection reported ever having prescribed PrEP. Among providers who had prescribed PrEP, 74% reported having prescribed for MSM, 30% for WSM, 23% for MSW, 23% for uninfected partners in HIV-discordant couples trying to conceive, and 1% for PWID (Table 2) . More male compared with female providers reported having prescribed PrEP (32% vs 16%, P = .0003) as did more lesbian/gay/ bisexual compared with heterosexual providers (50% vs 21%, P = .0082) ( Table 3 ). Human immunodeficiency virus caseload was also associated with having prescribed PrEP (>200, 51-200, and ≤50 patients, 39%, 29%, and 14%, respectively; P = .003). The following provider characteristics were not associated with prescribing PrEP: age, race/ethnicity, profession, physician board certification, years caring for HIV-infected patients, percentage of patients for whom ART is deferred for any reason, delivery of comprehensive sexual risk reduction services to patients with HIV, proportion of non-white patients, and practicing at a facility with RWHAP funding or onsite adherence counseling.
Using a multivariate model that included provider's gender and sexual orientation, HIV patient caseload, and whether >50% of the provider's patients were MSM, the following provider characteristics were associated with having prescribed PrEP: male vs female gender (adjusted prevalence ratio [aPR], 1.5; 95% CI, 1.0-2.2), lesbian/gay/bisexual vs heterosexual orientation (aPR, 2.0; 95% CI, 1.3-2.9), patient caseload of >200 vs ≤50 (aPR, 2.4; 95% CI, 1.1-5.2), and patient caseload of 51-200 vs ≤50 (aPR, 2.2; 95% CI, 1.2-4.0) ( Table 3) .
DISCUSSION
In 2013-2014, 1 in 4 US HIV care providers who also cared for HIV-negative patients reported having prescribed PrEP. Three quarters of those who prescribed PrEP, prescribed for MSM, which is not surprising considering that 25% of HIV-negative MSM (an estimated 492 000 persons) have indications for PrEP [20] . One third prescribed for WSM and one quarter prescribed for MSW. Only 1% prescribed PrEP for PWID [20] . Half of lesbian/gay/bisexual providers had prescribed PrEP compared with 1 in 5 of their heterosexual counterparts, and, after accounting for provider, patient, and practice characteristics, lesbian/gay/bisexual providers were twice as likely to have prescribed PrEP. Providers with HIV caseloads over 50 compared with those with smaller caseloads were also twice as likely, and male providers compared with female providers were 50% more likely to have prescribed PrEP.
Our estimate that 26% of HIV care providers had prescribed PrEP falls within the range of studies of members of the American Academy of HIV Medicine in 2011 (19%) [8] and clinicians affiliated with the New England AIDS Education and b Respondents were asked to indicate, on a 5-point Likert scale, the range for the percentage of patients to whom they offered 9 sexual risk-reduction services. Providers were categorized by whether they offered at least 7 services to most or all patients. Training Center in 2013 (19%) [9] , and a national network of US and Canadian ID physicians surveyed in September 2014 (32%) [11] after release of the CDC PrEP guidelines in May 2014 [7] . Unlike previous studies, because of our sampling and weighting methods, our estimates have the advantage of being representative of all US HIV care providers who also care for HIV-negative patients. In all, a relatively small proportion of these providers had prescribed PrEP considering the large body of evidence supporting its effectiveness, their familiarity with prescribing tenofovir/emtricitabine as a component of combination ART, and their experience providing other HIV risk reduction practices. Our survey was conducted before release of the formal clinical practice guidelines for PrEP in 2014, so our findings do not reflect their publication. However, CDC interim guidance for PrEP [21] [22] [23] had been published before our survey. In previous surveys, HIV care providers have consistently named several barriers to prescribing PrEP, including concerns about low treatment adherence with subsequent HIV infection resulting in the emergence of viral resistance to tenofovir/ emtricitabine, medication toxicity, an increase in risk behavior among patients taking PrEP, lack of medication coverage, the amount of time required of providers to prescribe PrEP, and a lack of demand [8] [9] [10] . Unlike previous studies, this analysis examined associations between PrEP prescribing and provider and practice characteristics, which could be useful for identifying groups of providers who need additional support to prescribe PrEP. One key finding was that lesbian/gay/bisexual providers were more likely than heterosexual providers to report having prescribed PrEP, and this relationship was independent of the proportion of MSM patients in their practices. Provider age, race/ethnicity, profession, board certification, and whether the provider practiced at a RWHAP-funded facility were not associated with PrEP prescribing, and are therefore also unlikely to explain the association between provider sexual orientation and PrEP prescribing. One possible explanation is that lesbian/gay/bisexual providers may be more aware of the sexual orientation of MSM patients and thus might be more likely to ask about indications for PrEP, such as condomless anal sex [7] , in this population. In a study of physicians' awareness of patients' sexual orientation, researchers found that MSM who thought their PCPs were gay were 35% more likely to report that their PCPs were aware of their sexual orientation [24] , and among Veterans Health Administration healthcare workers, more positive attitudes toward gay people, which were more common among non-heterosexuals, were associated with higher rates of asking patients about sexual orientation 25.
Our observation that male HIV care providers were 50% more likely than female providers to prescribe PrEP was independent of provider sexual orientation or any of the other variables we assessed. The relationship between patient-provider gender concordance and sexual history-taking has been examined among physicians in multispecialty practices affiliated with major teaching hospitals [26] . Researchers found that physicians perceived that their own comfort level and that of their patients are highest during same-gender sexual history interviews. One in 5 male physicians compared with half of female physicians reported discomfort taking sexual histories with male patients. Analogous findings were reported from a Colorado survey of 1300 PCPs in which more female than male providers obtained sexual histories from female patients [27] . The relationship between gender concordance and the rate and quality of sexual-history taking is an area for future qualitative research with patients and providers.
The higher likelihood of PrEP prescribing among providers with larger HIV patient caseloads was not unexpected given their greater familiarity with the medications prescribed for PrEP, which are also prescribed to treat HIV infection. Primary care providers without experience treating patients with HIV, but who may care for patients at risk for acquiring HIV, are likely to be even less knowledgeable about and experienced with provision of PrEP than low-volume HIV care providers, as observed among Massachusetts physicians in 2010-2011 [28] and among a broad cross-section of PCPs in 2013-2014, of whom 4% had prescribed PrEP [12] .
Only 1% of HIV care providers who reported having prescribed PrEP, prescribed for PWID, possibly reflecting the relatively small population estimate of past-year injection drug use (IDU) of 0.3% [29] . Although the annual number of new HIV diagnoses among PWID has declined, in 2014 an estimated 6% (2635) of HIV diagnoses were attributed to IDU [1] . In 2014, for the first time, injection of prescription opioids was linked to an outbreak of HIV in a rural US community [30] , and the CDC has identified an additional 220 counties that are vulnerable to rapid spread of HIV, if introduced, among PWID [31] . An estimated 115 000 PWID in the United States have indications for PrEP [20] . Considering the efficacy and safety demonstrated in the PrEP trial with PWID [6] , prescribing PrEP for persons with injection behaviors that place them at substantial risk of acquiring HIV infection could contribute to HIV prevention for PWID at both the individual and the population level [7] . In contrast to the limited experience of HIV care providers prescribing PrEP for PWID, 22% of a broad distribution of PCPs who had prescribed PrEP reported prescribing for PWID [12] . One possible explanation is that HIV care providers' decision whether to offer PrEP may be influenced by their experience prescribing ART for HIV-infected PWID. Human immunodeficiency virus care providers who reported that they sometimes deferred prescribing ART cited concerns about treatment adherence due to substance abuse as a common reason for deferring [32] . Similar concerns about adherence to PrEP could cause some HIV care providers to defer prescribing for PWID.
Our study had limitations. Our estimates were based on self-reported prescribing practices and may have been subject to measurement error due to inaccurate recall, although we have no reason to believe that one group of providers was more affected than another. Beyond determining the proportion of MSM in providers' practices, we were unable to assess the number of patients who requested PrEP or met the risk threshold for a recommendation of PrEP, which could have affected providers' prescribing experience. Third, we were unable to quantify the number of patients for whom, or over what period of time, providers had prescribed PrEP because they were asked only if they had ever prescribed PrEP. Finally, 3.5% of survey respondents did not specify their sexual orientation. Therefore, the precision of our estimate of the percentage of providers who were lesbian, gay, or bisexual may be limited by missing data.
CONCLUSIONS
In conclusion, in 2013-2014, one quarter of US HIV care providers who also cared for HIV-negative patients reported having prescribed PrEP, most commonly for MSM. Experience prescribing PrEP for PWID was limited, and improving access to PrEP in this population could help reduce HIV incidence among PWID. Providers who were lesbian/gay/bisexual or male were substantially more likely than others to have prescribed PrEP. Additional efforts, including training to elicit comprehensive sexual health histories regardless of gender concordance and training in the care of PWID, may enable more providers to prescribe PrEP to underserved patients who might benefit from this service.
